ethylpyrazine + rifampicide

Ethylpyrazine + rifampicide is a combination drug under investigation for the treatment of drug-resistant pulmonary tuberculosis. The formulation combines ethylpyrazine, a derivative or analog related to pyrazinamide (an established anti-tuberculosis agent), with rifampicide, which appears to be an alternative or modified form of the well-known antibiotic rifampicin (also called rifampin). This combination is being studied as part of clinical trials targeting patients with drug-sensitive and potentially drug-resistant forms of pulmonary tuberculosis. The mechanism of action likely involves inhibition of mycobacterial cell wall synthesis and interference with nucleic acid synthesis, similar to their parent compounds. Clinical development has been reported in China, including at Beijing Chest Hospital and West China Hospital[7][8].